Pharmaceutical Technology

MAY 11, 2023

Bayer has entered a strategic collaboration agreement with biotechnology company Bicycle Therapeutics to discover, develop, manufacture and commercialise Bicycle’s radioconjugates for a number of oncology targets. Bicycle will receive an upfront payment of $45m and up to $1.7bn as potential development and commercially based milestone fees.

Development 162

Development Manufacturing Protein Clinical Development 162

The Pharma Data

NOVEMBER 30, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. Novavax completed enrollment of 15,000 participants in a pivotal Phase 3 clinical trial being conducted in the U.K. Novavax was awarded $1.6

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

Pharmaceutical Technology

FEBRUARY 20, 2023

ABN-401 is under clinical development by Abion and currently in Phase II for Solid Tumor. It conducts research activities to develop biopharmaceutical drugs and companion diagnostic systems for the treatment of incurable diseases. Abion overview Abion is a biopharmaceutical company.

Protein 100

Protein Clinical Trials Clinical Trials Drugs 100

Drug Discovery World

FEBRUARY 2, 2024

The company is building a pipeline of small molecule drugs targeting novel proteins across the DNA mismatch repair (MMR) pathway to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. NeoPhore has announced a further extension of £9.6 million (approximately $12.2 million).

Protein 52

Protein DNA Clinical Development Drugs 52

The Pharma Data

JULY 22, 2021

NYSE: PFE) today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The companies will equally share worldwide development costs, commercialization expenses, and profits. (Nasdaq: ARVN) and Pfizer Inc.

Protein 52

Protein Development HR Hormones 52

Drug Discovery World

MAY 11, 2023

They are chemically synthesisable, featuring a low molecular weight and tunable pharmacokinetics, with a large surface-area for molecular interactions that allows protein-protein interactions to be targeted. The two companies will jointly use Bicycle’s peptide technology to develop bicyclic peptides for several oncology targets.

Manufacturing 97

Manufacturing Protein Clinical Development Development 97

Pharmaceutical Technology

DECEMBER 6, 2022

Until 2025, the companies will equally share the research and intellectual property licensing expenses under the partnership. Under a possible development and commercialisation agreement in the future for the CMV vaccine candidate discovered by the parties, Evaxion will be entitled to receive upfront and milestone payments from ExpreS 2 ion.

Vaccination 130

Vaccination Vaccine Development Immune Response 130

Pharmaceutical Technology

AUGUST 17, 2022

oRNA molecules have been demonstrated to possess increased stability in vivo compared to linear mRNA and can potentially create more quantities of therapeutic proteins within the body. . By self-circularisation, Orna’s oRNA technology makes circular ribonucleic acids (oRNAs) from linear RNAs.

RNA 147

RNA Vaccination Vaccine In-Vivo 147

Pharmaceutical Technology

MAY 31, 2023

ATRN-119 is under clinical development by Aprea Therapeutics and currently in Phase II for Solid Tumor. Aprea Therapeutics overview Aprea Therapeutics is a biopharmaceutical company that develops cancer therapeutics that reactivate mutant tumor suppressor protein, p53.

Production 100

Production Clinical Trials Clinical Trials Development 100

Drug Discovery World

APRIL 22, 2024

In a study published in Cell Reports , scientists at The Institute of Cancer Research, London, have uncovered how cells know what environment they are in and therefore which shape to choose. This research has given us insight into the tricks that cancer cells are using to keep growing and spreading.”

Drugs 52

Drugs Gene Scientist Research 52

XTalks

APRIL 11, 2024

Approaches to help better understand the complexities of brain function are key to advancing the development of novel treatments for Alzheimer’s disease. It’s one thing to look at how proteins are changing in the brain and even how the structure is changing.

Clinical Trials 110

Clinical Trials Clinical Trials Development Clinical Development 110

Drug Discovery World

MARCH 26, 2024

DDW’s Megan Thomas caught up with Oliver Rausch, Chief Scientific Officer at Storm Therapeutics, following the ESMO Targeted Anticancer Therapies Congress 2024, a global meeting focusing on promising new anticancer targets and agents, focusing on those in early phase clinical development. MT: What’s next for STORM’s research?

RNA 64

RNA In-Vivo In-Vitro DNA 64

pharmaphorum

DECEMBER 4, 2020

Valneva has said it plans to accelerate research into its Lyme disease vaccine candidate VLA15, bringing forward a trial including children into the first quarter of 2021. Valneva is paying 30% of development costs and in return Pfizer will pay tiered royalties starting at 19% and will lead late-stage development.

Vaccination 118

Vaccination Vaccine Bacterium Protein 118

Drug Discovery World

JULY 6, 2023

The first patient has been dosed in the clinical Phase I evaluation of the Sema3A monoclonal antibody, part of the Evotec-Bayer multi-target research collaboration in kidney diseases. Semaphorin-3A is an extracellular guidance protein and a well-known regulator of the actin cytoskeleton.

Antibody 52

Antibody Trials Genetics Protein 52

Pharmaceutical Technology

MAY 31, 2023

Sym-021 is under clinical development by Les Laboratoires Servier and currently in Phase I for Solid Tumor. The therapeutic candidate targets immune checkpoint, programmed cell death protein 1 (PD1). It is developed based on sympress platform technology. It is administered as an intravenous infusion.

Generic Drugs 100

Generic Drugs Hormones Manufacturing Development 100

Drug Discovery World

MAY 25, 2023

The modular, cloud native Torx platform enables chemistry teams to collaborate and share molecules, both internally and with contract research organisations (CROs) around the world. It is accessible, boosts developer productivity and aims to save up to 80% of the time and cost associated with traditional API management strategies.

Production 52

Production Reagent DNA Drugs 52

Pharmaceutical Technology

FEBRUARY 9, 2023

Buntanetap tartrate is under clinical development by Annovis Bio and currently in Phase III for Parkinson’s Disease. It acts by targeting amyloid precursor protein (APP), tau and alpha-synuclein. It was also under development for the treatment of Huntington’s disease and traumatic brain injury.

Clinical Trials 100

Clinical Trials Clinical Trials Drugs Development 100

Pharmaceutical Technology

FEBRUARY 9, 2023

Buntanetap tartrate is under clinical development by Annovis Bio and currently in Phase III for Alzheimer’s Disease. It acts by targeting amyloid precursor protein (APP), tau and alpha-synuclein. It was also under development for the treatment of Huntington’s disease and traumatic brain injury.

Clinical Trials 100

Clinical Trials Clinical Trials Drugs Development 100

Roots Analysis

FEBRUARY 27, 2024

On November 1, 2019, Avacta Group and ADC Therapeutics have announced a collaboration agreement for the development of novel drug candidates. The firm also has the right to obtain exclusive licenses to the Affimer proteins for clinical development and commercialization.

Antibody 52

Antibody Licensing Licensing Contract Manufacturing 52

The Pharma Data

JUNE 1, 2022

has been appointed Senior Vice President and Head of the Company’s Vaccine Research & Development (R&D) organization effective August 1, succeeding Kathrin U. Anderson most recently served as Vice President and Chief Scientific Officer for Bacterial Research and Hospital within the Vaccine R&D organization.

Vaccination 40

Vaccination Vaccine Development Research 40

Roots Analysis

MAY 21, 2024

Proteins are the chains of amino acids linked together in different combinations and perform a wide variety of functions. However, continuous regulation of the cellular proteome is essential for maintaining the right balance of different proteins necessary for normal cellular function, survival, and proliferation.

Protein 40

Protein Marketing Development Antibody 40

Delveinsight

AUGUST 13, 2020

Researchers call out Gilead over the diversity of remdesivir trials. Researchers have challenged the sponsors of COVID-19 clinical trials to run more diverse studies. The researchers cite data in the New England Journal of Medicine, showing Black Americans account for a disproportionate number of COVID-19 cases in the U.S.

Trials 52

Trials Research Drugs Protein 52

The Pharma Data

APRIL 15, 2022

A new protein-based antiviral nasal spray developed by researchers at Northwestern University, University of Washington and Washington University at St. Louis is being advanced toward Phase I human clinical trials to treat COVID-19. “Our minibinders sit on top of the spike protein like a tripod and block all three.

Antibody 52

Antibody Protein Engineer Manufacturing 52

The Pharma Data

JANUARY 12, 2021

Dark Antigens are in reference to a newer class of cancer antigens derived from a portion of the human genome not normally expressed as a protein. Additionally, Boehringer has been granted the responsibility for all non-clinical as well as clinical development. Source link.

Research 52

Research Genome Genomics Licensing 52

Pharmaceutical Technology

FEBRUARY 26, 2023

CUE-102 is under clinical development by Cue Biopharma and currently in Phase I for Metastatic Colorectal Cancer. It is composed of IL-2 and a pMHC complexed with a dominant peptide derived from the from the Wilms’ Tumor protein. It is developed using Immuno-STAT technology.

Drugs 100

Drugs Clinical Trials Clinical Trials Development 100

Pharmaceutical Technology

FEBRUARY 26, 2023

CUE-102 is under clinical development by Cue Biopharma and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. It is composed of IL-2 and a pMHC complexed with a dominant peptide derived from the from the Wilms’ Tumor protein. It is developed using Immuno-STAT technology.

Drugs 100

Drugs Clinical Trials Clinical Trials Development 100

pharmaphorum

JANUARY 25, 2021

With over 23 world-class speakers set to share their ground-breaking research developments, straight to your home or office, this is your chance to learn from the industry’s very best, including: Mitokinin showcasing how activating PINK1 dependent mitochondrial quality control to treat Parkinson’s disease. Don’t miss out!

Development 98

Development Drugs Protein Clinical Development 98

Camargo

JULY 27, 2021

When developing a clinical development program for these increasingly popular therapies, it is important that sponsors use modeling and pharmacokinetic (PK) analysis to evaluate parameters that can be measured while dosing with gene therapy drugs, to characterize exposure-response data and inform rational dosing.

Gene Therapy 238

Gene Therapy Gene Gene Editing Genetics 238

The Pharma Data

DECEMBER 13, 2020

2] Pre-clinical studies have shown that these differentiated properties of HMBD-001 lead to robust and sustained tumor growth inhibition in multiple HER3 cancer models, including those with NRG1-fusions. Our highly experienced teams in Singapore and the US span antibody discovery, pharmacology, production and clinical development.

Clinical Development 52

Clinical Development Medicine Development Antibody 52

pharmaphorum

JANUARY 13, 2022

Clinical trials will be needed to see if doing so can interrupt the neurodegeneration seen in Parkinson’s. Alpha-synuclein is a protein that gets misfolded and clumps together in the brains of patients with Parkinson’s and other diseases collectively known as synucleinopathies.

Antibody 98

Antibody Drugs Protein Licensing 98

Drug Discovery World

AUGUST 28, 2023

DS: Samsara’s autophagy inducing candidate SAM001 will be the first agent of its class to enter clinical trials. It is the method for removing unwanted debris, e.g., old proteins, and breaking them down so their constituent parts can be used again. What are the challenges of research in this area? What is autophagy?

Genetics 52

Genetics Protein Genetic Disease Clinical Trials 52

Delveinsight

DECEMBER 24, 2020

research institutions. Examples include the development of breathalyzers capable of diagnosing a COVID-19 infection and detectors, recognizing the airborne virus in open spaces, such as meeting rooms and hospital hallways. GPR35 is a G protein-coupled receptor (GPCR) that was recognized in the late 1990s.

Research 52

Research Trials Clinical Trials Clinical Trials 52

Drug Discovery World

JANUARY 15, 2024

Chiesi and Oak Hill Bio Chiesi Group and Oak Hill Bio have entered a collaboration to develop OHB-607, a clinical-stage investigational drug candidate to treat complications of extremely premature birth.

Drugs 59

Drugs Licensing Licensing Protein 59

Pharmaceutical Technology

JULY 7, 2022

A new frontier in cancer research. Cell and gene therapies are currently at the forefront of immunotherapy cancer research, and a few approved therapies are already making a difference to disease outcomes for patients.

Gene Therapy 245

Gene Therapy Gene Medicine Genetics 245

Roots Analysis

FEBRUARY 26, 2024

Given the robust pipeline of biologics, which include monoclonal antibodies, vaccines and other protein-based therapeutic products, subcutaneous medications are being investigated for various clinical candidates across different phases of development.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Drugs Contract Manufacturing 52

pharmaphorum

SEPTEMBER 1, 2020

The world of drug discovery and chemical probes is still protein-centric and developing highly selective small molecules targeting RNA is often considered to be an insurmountable challenge.

RNA 52

RNA Drugs Protein Clinical Development 52

pharmaphorum

SEPTEMBER 14, 2020

It uses a weakened, non-replicating, version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 coronavirus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

Vaccination 101

Vaccination Vaccine Trials Protein 101